Published Date: 17 Jun 2024
Also in TTHealthWatch: cancers subsequent to CAR-T therapy
Read Full NewsAn AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.
Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.
Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms
Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms
Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies
Young Adults With Glomerular Disease May Require Distinct Care
Q4 2025 Recap: Nephrology News and Updates
1.
Disparities in use of MRI to detect prostate cancer: Race and location may influence testing
2.
Prior authorizations draining time, energy from many cancer patients
3.
Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.
4.
novel technique for early myelodysplastic syndrome relapse detection in blood cancer patients.
5.
The hidden costs of cancer for young survivors are derailing their financial futures
1.
Understanding Leiomyoma: Causes, Symptoms, and Treatment Options
2.
Malignant Prolactinoma: Prolactin Surge with Minimal Growth Masks Widespread Metastases
3.
Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans
4.
Case Study: The Role of Machine Learning in the Detection of Skin Cancer
5.
Exploring the Normal Range of Monocytes: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation